Implant Sciences' QS-B220 Explosives Trace Detector Receives STAC Certification in France
- Highly Respected Certification Opens Large Market Opportunity in Airport Screening Throughout Europe
Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its TSA-approved QS-B220 desktop explosives trace detector (ETD) has been certified by Service Technique de l'Aviation Civile (STAC) in France. The QS-B220 is now certified for purchase and deployment to screen passengers, cargo, cabins, and baggage for explosives in airports throughout France. This marks the second major regulatory success for the QS-B220 following its approval by the U.S. Transportation Security Administration (TSA) for air cargo screening in January 2013.
"This is a very significant achievement and milestone for Implant Sciences. STAC is a highly respected certification organization, and becoming certified opens the large French aviation market to us. A number of other governments including French territories, several European Union member nations, and a select number of countries around the world look to STAC certification in their purchasing decisions," stated Implant Sciences' President and CEO, Glenn Bolduc. "This is another step in our journey towards increasing our global market share and further establishing Implant Sciences as one of the major ETD manufacturers in the world."
Drone Payload Market - Global Forecast to 2021
"As a STAC-certified ETD with a non-radioactive source, the QS-B220 proves again that Implant Sciences is the new standard in trace detection," commented Darryl Jones, Implant Sciences' Vice President of Sales and Marketing. "Regulations on equipment containing radioactive materials are much stricter in France and other European nations than in the U.S., and we believe that there is a significant market opportunity for us with airports and other security customers that may have been reluctant to purchase competing ETD devices with a radioactive ion source."
Source : Implant Sciences Corp.
Mar 29 - 30, 2017 - London, United Kingdom